HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21
Onkure Therapeutics Inc OKUR
$3.82
โผ -4.50%
($-0.18)
🗓️ Earnings Next Week
Open
$3.99
Prev Close
$4.00
Day Range
$3.72 โ $4.01
52W Range
$1.91 โ $5.38
Market Cap
$154.31M
Beta
0.24
EPS (TTM)
$-4.33
๐ Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-09 |
| Shares Out. | 40,400,000 |
| Website | onkuretherapeutics.com/ โ |
| Phone | 17203072892 |
| Employees | 45 |
| Net Income | -$15.2M |
| Free Cash Flow | -$50.8M |
| Total Assets | $198.7M |
| Total Liabilities | $14.3M |
| Equity | $184.4M |
About Onkure Therapeutics Inc
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kฮฑ. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
Onkure Therapeutics Inc is a publicly traded company under the ticker symbol OKUR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
12 analysts (2026-07-01)